期刊文献+

鼻腔鼻窦恶性纤维组织细胞瘤11例临床分析 被引量:2

在线阅读 下载PDF
导出
摘要 目的探讨鼻腔鼻窦恶性纤维组织细胞瘤的临床特点。方法对1990年1月至2010年1月收治的11例原发于鼻腔、鼻窦的恶性纤维组织细胞瘤的临床表现、诊断、治疗方法和随访结果进行分析。结果鼻腔鼻窦恶性纤维组织细胞瘤临床症状多样化,诊断主要依靠病理,治疗采用根治性手术结合放疗,11例患者中随访10例,失访1例,3年生存率为45.5%(5/11),5年生存率为36.4%(4/11)。结论鼻腔鼻窦恶性纤维组织细胞瘤临床症状不典型,恶性程度高,易复发。预后有赖于病理分型和临床分期。早期诊断、根治性手术加术后放疗是提高本病生存率的关键。
出处 《济宁医学院学报》 2015年第5期336-338,共3页 Journal of Jining Medical University
  • 相关文献

参考文献4

二级参考文献47

  • 1吴雪溪,祁永发,唐平章.A comparison of malignant fibrous histiocytoma of head, neck and extremities[J].Chinese Medical Journal,2000(6):52-55. 被引量:5
  • 2唐卫华,汪筱娟,乔柏生,刘景琴,许复郁.骨原发恶性纤维组织细胞瘤(组织学、电镜及免疫组织化学研究)[J].山东医科大学学报,1994,32(4):275-280. 被引量:8
  • 3李雯,赖日权,安建成,田野.骨原发性恶性纤维组织细胞瘤的病理形态及免疫组化观察[J].肿瘤防治研究,1994,21(6):342-343. 被引量:6
  • 4Ri-Sheng Yu,Ying Chen,Biao Jiang,Liu-Hong Wang,Xiu-Fang Xu.Primary hepatic sarcomas: CT findings[J]. European Radiology . 2008 (10)
  • 5Fletcher CD,,Gustafson P,Rydholm A,Willén H,Akerman M.Clinicopathologic re-evaluation of 100 malignant fibrous histiocytomas: prognostic relevance of subclassification. Journal of Clinical Oncology . 2001
  • 6Fletcher,CD.Pleomorphic malignant fibrous histiocytoma: fact or fiction? A critical reappraisal based on 159 tumors diagnosed as pleomorphic sarcoma. The American Journal of Surgical Pathology . 1992
  • 7Weiss SW,Enzinger FM.Malignant fibrous histocytoma: An analysis of 200 cases. Cancer . 1978
  • 8Satoshi Hasegawa,Hiroshi Kawachi,Haruki Kurosawa,Yoshiroh Obi,Ken Yamanaka,Kyoichi Nakamura,Tetsuo Abe.CASE REPORT: Malignant Fibrous Histiocytoma in the Ileum Associated with Intussusception[J]. Digestive Diseases and Sciences . 2004 (7-8)
  • 9A. E. Rosenberg.Malignant fibrous histiocytoma: past, present, and future[J]. Skeletal Radiology . 2003 (11)
  • 10Konstantinos S. Atmatzidis,Theodoros E. Pavlidis,Ioannis N. Galanis,Basilios T. Papaziogas,Thomas B. Papaziogas.Malignant Fibrous Histiocytoma of the Abdominal Cavity: Report of a Case[J]. Surgery Today . 2003 (10)

共引文献30

同被引文献28

  • 1Mader M M,Henry J R.Antimetabolites,Comprehensive Medicinal Chemistry(11),[M].2007,Volume 7,55-79.
  • 2Magge R S,Deangelis L M.The double-edged sword: Neurotoxicity of chemotherapy[J].Blood Rev,2015,29(2):93-100.DOI:10.1016/j.blre.2014.09.012.
  • 3Van Den Neste E,Van Den Berghe G,Bontemps F.AI- CA-riboside(acadesine),an activator of AMP-activated protein kinase with potential for application in hemato- logic malignancies[J].Expert Opin Investig Drugs,2010,19(4):571-578.DOI:10.1517/13543781003703694.
  • 4Zeidler J,Baraniak D,Ostrowski T.Bioactive nucleoside analogues possessing selected five-membered azahetero- cyclic bases[J].Eur J Med Chem,2015,97(5):409-418.DOI:10.1016/j.ejmech.2014.11.057.
  • 5Musto P,Maurillo L,Spagnoli A A,et al.Azacitidine for the treatment of lower risk myelodysplastic syndromes [J].Cancer,2010,116(6):1485-1494.DOI:10.1002/ cncr.24894.
  • 6Momparler R L,C6t6 S,Momparler L F.Epigenetic ac- tion of decitabine(5-aza-2-deoxycytidine)is more ef- fective against acute myeloid leukemia than cytotoxic ac- tion of cytarabine(ARA-C)[J].Leuk Res,2013,37(8):980-984.DOI:10.1016/j.leukres.2013.04.019.
  • 7Reese N D,Schiller G J.High-dose cytarabine(HD araC)in the treatment of leukemias:a review[J].Curr Hematol Malig Rep,2013,8(2):141-148.DOI:10.1007/sl 1899-013-0156-3.
  • 8Ogura M,Tsukasaki K,Nagai H,et al.Phase I study of BCXl 777(forodesine)in patients with relapsed or re- fractory peripheral T/natural killer-cell malignancies [J].Cancer Sci,2012,103(7):1290-1295.DOI:10.1111/j.1349-7006.2012.02287.
  • 9Waud W R,Gilbert K S,Secrist J A.Preclinical antitu- mor activity of thiarabine in human leukemia and lym- phoma xenograft models[J].Nucleosides Nucleotides Nucleic Acids,2012,31(9):647-660.DOI:10.1080/15257770.2012.710768.
  • 10Mar^chal R,Mackey J R,Lai R,et al.Deoxycitidine ki- nase is associated with prolonged survival after adjuvant gemcitabine for resected pancreatic adenocarcinoma[J]. Cancer,2010,116(22):5200-5206.DOI:10.1002/ cncr.25303.

引证文献2

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部